DON’T IGNORE CHRONIC REFLUX
When diagnosis and treatment are delayed, chronic GORD can increase your risk for serious health complications, including Barrett’s Oesophagus and oesophagus cancer.2
SYMPTOMS OF GORD & RISK OF PROGRESSION
Acid reflux is considered GORD if moderate to severe symptoms occur once a week. To know for sure if these are symptoms of GORD, consult a gastroenterologist (GI).
Difficult swallowing, heartburn, regurgitation and other symptoms of GORD are not only uncomfortable, they may signify a more serious condition.3
Without intervention, 26.5% of chronic GORD patients may develop a precancerous condition called Barrett’s Oesophagus.4
ASSESS YOUR RISK
Complete this short risk assessment quiz to understand your risk level for Barrett’s Oesophagus and oesophagus cancer. Share the results with your doctor at your next appointment.DOWNLOAD TOOL
BARRETT'S OESOPHAGUS AND OESOPHAGUS CANCER
Barrett’s is the primary risk factor for oesophageal adenocarcinoma.5,6,7 Untreated Barrett's Oesophagus can increase your risk of developing this form of cancer by 30-60 fold.5,8
If detected early, it's possible to treat Barrett’s Oesophagus and reduce your risk for oesophageal adenocarcinoma.9,10
Information and resources on this site should not be used as a substitute for medical advice from your doctor. Always discuss diagnosis and treatment information including risks with your doctor. Keep in mind that all treatment and outcome results are specific to the individual patient. Results may vary.
Shaheen N, RansohoffDF. Gastroesophageal reflux, Barrett’s esophagus and esophageal cancer. JAMA. 2002;287:1972-81.
Dymedex Market Development Consulting, Strategic Market Assessment, GERD, October 30, 2014. References 1-3, 6-15, 22, 23, 25, and 34 from the full citation list, access at http://www.medtronic.com/giclaims.
Vaezi M, Zehrai A, Yuksel E. Testing for refractory gastroesophageal reflux disease. ASGE Leading Edge. 2012;2(2):1-13. American Society Gastroenterology Endoscopy, Pages 1-4.
Dymedex Market Development Consulting, Strategic Market Assessment, GERD, October 30, 2014. References .1-3, 6-15, 22, 23, 25, and 34 from the full citation list, access at http://www.medtronic.com/giclaims.
De Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59:1030-6
Pohl H, Welch G et al. The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-6.
Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375-83
Gilbert EW et al. Barrett’s esophagus: a review of the literature. J Gastrointest Surg. 2011;15:708-1.
Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett's esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245-55.
PhoaKN, van Vilsteren FG, Pouw RE, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014 Mar 26;311(12):1209-17.